{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:20:41Z","timestamp":1780989641689,"version":"3.54.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Posaconazole immediate release (IR) suspension is the standard product for enteral feeding tube (EFT) administration but has erratic pharmacokinetic behaviour, often resulting in subtherapeutic concentrations. Limited evidence suggests that posaconazole oral delayed-release (DR) tablets may be crushed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective cohort study of hospitalized adults who received EFT administration of posaconazole IR suspension or crushed DR tablets between 2018 and 2024. Patients were eligible if they had at least one serum drug concentration drawn \u22655\u2005days after posaconazole initiation. The primary outcome was attainment of therapeutic drug concentrations. Secondary outcomes included time to therapeutic serum concentration, adverse drug events, and frequency of occluded EFT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the included patients, 48 received IR suspension and 100 received DR tablets. Baseline characteristics and severity of illnesses were well balanced. Among IR suspension and crushed DR tablet recipients, 39% and 80% achieved therapeutic concentrations, respectively (P\u200a=\u200a0.002). After adjusting for age, sex, BMI, drug interactions, posaconazole indication and malabsorptive conditions, crushed DR tablets were significantly more likely than IR suspension to achieve therapeutic posaconazole concentrations within 30\u2005days (HR 5.22, 95% CI 2.35\u201311.61). Occluded EFTs were more frequent among crushed DR tablet recipients (27% versus 10%, P\u200a=\u200a0.022), while no differences were observed in the occurrence of hepatotoxicity or hypokalaemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>With EFT administration, crushed posaconazole DR tablets were associated with a greater likelihood of achieving therapeutic concentrations compared with IR suspension. The optimal technique for administering crushed DR tablets to prevent EFT complications warrants investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf396","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:10:44Z","timestamp":1760011844000},"source":"Crossref","is-referenced-by-count":2,"title":["Posaconazole enteral tube administration in adults: pharmacokinetic target attainment of oral suspension compared with crushed delayed-release tablet"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7994-4209","authenticated-orcid":false,"given":"Nirjan","family":"Bhattarai","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic , 200 First St SW, Rochester, MN 55902 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5050-6689","authenticated-orcid":false,"given":"Ryan W","family":"Stevens","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic , 200 First St SW, Rochester, MN 55902 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M","family":"Wieruszewski","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic , 200 First St SW, Rochester, MN 55902 ,","place":["USA"]},{"name":"Department of Anesthesiology, Mayo Clinic , 200 First St SW, Rochester, MN 55902 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0778-3901","authenticated-orcid":false,"given":"Dan","family":"Ilges","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic Arizona , 5777 E. Mayo Blvd, Phoenix, AZ 85054 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C","family":"Robinson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic Arizona , 5777 E. Mayo Blvd, Phoenix, AZ 85054 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin C","family":"Cole","sequence":"additional","affiliation":[{"name":"Division of Clinical Trials and Biostatistics, Mayo Clinic , 200 First St SW, Rochester, MN 55902 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey R","family":"O\u2019Connell","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic , 200 First St SW, Rochester, MN 55902 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9181-8347","authenticated-orcid":false,"given":"Tanner M","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic , 200 First St SW, Rochester, MN 55902 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"2026011413265993700_dkaf396-B1","doi-asserted-by":"publisher","first-page":"e00242-18","DOI":"10.1128\/AAC.00242-18","article-title":"Pharmacokinetics of intravenous posaconazole in critically ill patients","volume":"62","author":"Sime","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413265993700_dkaf396-B2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.clnu.2005.08.013","article-title":"Enteral nutrition delivery and energy expenditure in medical intensive care patients","volume":"25","author":"Petros","year":"2006","journal-title":"Clin Nutr"},{"key":"2026011413265993700_dkaf396-B3","author":"Merck & Co"},{"key":"2026011413265993700_dkaf396-B4","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.1128\/AAC.00222-12","article-title":"Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension","volume":"56","author":"Krishna","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413265993700_dkaf396-B5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12281-016-0255-4","article-title":"Therapeutic drug monitoring of posaconazole: an update","volume":"10","author":"Dekkers","year":"2016","journal-title":"Curr Fungal Infect Rep"},{"key":"2026011413265993700_dkaf396-B6","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1128\/AAC.00496-15","article-title":"Retrospective comparison of posaconazole levels in patients taking the delayed-release tablet versus the oral suspension","volume":"59","author":"Durani","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413265993700_dkaf396-B7","doi-asserted-by":"publisher","first-page":"5758","DOI":"10.1128\/AAC.03050-14","article-title":"Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia","volume":"58","author":"Duarte","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413265993700_dkaf396-B8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/phar.1533","article-title":"Review of the new delayed-release oral tablet and intravenous dosage forms of posaconazole","volume":"35","author":"Guarascio","year":"2015","journal-title":"Pharmacotherapy"},{"key":"2026011413265993700_dkaf396-B9","doi-asserted-by":"publisher","first-page":"e02688-18","DOI":"10.1128\/AAC.02688-18","article-title":"Serum levels of crushed posaconazole delayed-release tablets","volume":"63","author":"Mason","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413265993700_dkaf396-B10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ijid.2022.09.004","article-title":"Factors associated with subtherapeutic levels of oral posaconazole tablet: a detailed analysis from a tertiary care center in India","volume":"124","author":"Prayag","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2026011413265993700_dkaf396-B11","doi-asserted-by":"publisher","first-page":"e0108522","DOI":"10.1128\/aac.01085-22","article-title":"Efficacy of crushed delayed-release posaconazole tablets in rhino-orbito-cerebral mucormycosis","volume":"66","author":"Manesh","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413265993700_dkaf396-B12","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/jac\/dkac035","article-title":"Enteral feeding tube administration with therapeutic drug monitoring of crushed posaconazole tablets and opened isavuconazonium sulfate capsules","volume":"77","author":"Dieringer","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026011413265993700_dkaf396-B13","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/jac\/dkac427","article-title":"Therapeutic drug monitoring following crushed administration of delayed-release posaconazole tablets via enteral feeding tubes","volume":"78","author":"Stevens","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026011413265993700_dkaf396-B14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/10600280241249705","article-title":"Crushed posaconazole delayed-release tablets via enteral feeding tubes: a cautionary tale","volume":"59","author":"Kane","year":"2025","journal-title":"Ann Pharmacother"},{"key":"2026011413265993700_dkaf396-B15","doi-asserted-by":"publisher","first-page":"e30782","DOI":"10.1002\/pbc.30782","article-title":"Successful enteral administration of crushed posaconazole delayed-release tablets in children","volume":"71","author":"Bio","year":"2024","journal-title":"Pediatr Blood Cancer"},{"key":"2026011413265993700_dkaf396-B16","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1093\/jac\/dkae373","article-title":"Crushed posaconazole delayed-release tablets for antifungal prophylaxis and treatment in children","volume":"79","author":"Weerdenburg","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026011413265993700_dkaf396-B17","doi-asserted-by":"publisher","first-page":"e14402","DOI":"10.1111\/tid.14402","article-title":"Evaluation of crushed posaconazole delayed release tablets in lung transplant recipients","volume":"27","author":"Gordon","year":"2025","journal-title":"Transpl Infect Dis"},{"key":"2026011413265993700_dkaf396-B18","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1093\/jac\/dkaf151","article-title":"Posaconazole dosing of enteral formulations in infants and young children to achieve therapeutic concentrations","volume":"80","author":"Harrington","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026011413265993700_dkaf396-B19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1177\/10600280241259484","article-title":"Administering crushed posaconazole delayed-release tablets should not be assumed to behave pharmacokinetically as if swallowed intact","volume":"59","author":"Stevens","year":"2025","journal-title":"Ann Pharmacother"},{"key":"2026011413265993700_dkaf396-B20","author":"Disclosure of Health Records for External Research"},{"key":"2026011413265993700_dkaf396-B21","doi-asserted-by":"publisher","first-page":"ofae185","DOI":"10.1093\/ofid\/ofae185","article-title":"Real-world experience of posaconazole therapeutic drug monitoring in oncology patients: clinical implications of hypoalbuminemia as a predictor of subtherapeutic posaconazole levels","volume":"11","author":"Handley","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026011413265993700_dkaf396-B22","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/FTD.0b013e31821fb197","article-title":"Posaconazole plasma concentrations in critically ill patients","volume":"33","author":"Ray","year":"2011","journal-title":"Ther Drug Monit"},{"key":"2026011413265993700_dkaf396-B23","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/jac\/dkv380","article-title":"Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease","volume":"71","author":"Cornely","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2026011413265993700_dkaf396-B24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2026011413265993700_dkaf396-B25","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2026011413265993700_dkaf396-B26","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1128\/AAC.05900-11","article-title":"Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413265993700_dkaf396-B27","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/phar.2850","article-title":"Utility of triazole antifungal therapeutic drug monitoring: insights from the Society of Infectious Diseases Pharmacists: endorsed by the Mycoses Study Group Education and Research Consortium","volume":"43","author":"McCreary","year":"2023","journal-title":"Pharmacotherapy"},{"key":"2026011413265993700_dkaf396-B28","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1586\/14787210.2013.826989","article-title":"Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis","volume":"11","author":"Seyedmousavi","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026011413265993700_dkaf396-B29","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"2026011413265993700_dkaf396-B30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"2026011413265993700_dkaf396-B31","doi-asserted-by":"publisher","first-page":"myad079","DOI":"10.1093\/mmy\/myad079","article-title":"Association of adverse effects with high serum posaconazole concentrations","volume":"61","author":"Jensen","year":"2023","journal-title":"Med Mycol"},{"key":"2026011413265993700_dkaf396-B32","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1093\/cid\/ciz741","article-title":"Posaconazole serum drug levels associated with pseudohyperaldosteronism","volume":"70","author":"Nguyen","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026011413265993700_dkaf396-B33","doi-asserted-by":"publisher","first-page":"s104","DOI":"10.7861\/clinmedicine.16-6-s104","article-title":"Drug-induced liver injury","volume":"16","author":"Katarey","year":"2016","journal-title":"Clin Med (Lond)"},{"key":"2026011413265993700_dkaf396-B34","volume-title":"StatPearls","author":"Castro","year":"2025"},{"key":"2026011413265993700_dkaf396-B35","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/phar.70021","article-title":"Correction of posaconazole concentrations for hypoalbuminemia","volume":"45","author":"Nix","year":"2025","journal-title":"Pharmacotherapy"},{"key":"2026011413265993700_dkaf396-B36","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2165\/00003088-200544020-00006","article-title":"Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations","volume":"44","author":"Ezzet","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"2026011413265993700_dkaf396-B37","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.1021\/acs.molpharmaceut.7b00396","article-title":"In silico modeling approach for the evaluation of gastrointestinal dissolution, supersaturation, and precipitation of posaconazole","volume":"14","author":"Hens","year":"2017","journal-title":"Mol Pharm"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf396\/64832348\/dkaf396.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf396\/64832348\/dkaf396.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:27:02Z","timestamp":1768415222000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf396\/8294484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf396","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,10,22]]},"article-number":"dkaf396"}}